Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel Sells 14,213 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel sold 14,213 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total transaction of $520,480.06. Following the sale, the director now directly owns 13,315 shares in the company, valued at approximately $487,595.30. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Supernus Pharmaceuticals Stock Up 0.5 %

Shares of Supernus Pharmaceuticals stock traded up $0.20 during mid-day trading on Friday, hitting $36.60. The stock had a trading volume of 578,615 shares, compared to its average volume of 452,714. Supernus Pharmaceuticals, Inc. has a 12-month low of $24.46 and a 12-month high of $39.37. The firm has a market cap of $2.02 billion, a P/E ratio of 34.02 and a beta of 0.86. The firm has a 50-day moving average of $33.11 and a two-hundred day moving average of $30.63.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.25. The business had revenue of $175.70 million during the quarter, compared to analysts’ expectations of $157.35 million. Supernus Pharmaceuticals had a return on equity of 7.79% and a net margin of 9.16%. The business’s quarterly revenue was up 14.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.29) EPS. Sell-side analysts expect that Supernus Pharmaceuticals, Inc. will post 1.53 earnings per share for the current year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of SUPN. GAMMA Investing LLC increased its stake in Supernus Pharmaceuticals by 97.1% in the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 398 shares in the last quarter. EntryPoint Capital LLC purchased a new position in shares of Supernus Pharmaceuticals in the first quarter valued at $43,000. Meeder Asset Management Inc. acquired a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth $47,000. Innealta Capital LLC acquired a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at about $51,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after acquiring an additional 352 shares in the last quarter.

Analyst Ratings Changes

Several analysts have weighed in on the company. Piper Sandler reiterated a “neutral” rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th. StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Finally, Cowen reaffirmed a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.